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Serum apolipoprotein profile of patients with chronic renal failure.
Serum concentrations of apolipoproteins A-I, A-Il, B, C-I, C-lI, C-Ill
and E were determined by electroimmunoassay in 56 patients with
chronic renal failure (CRF) in the predialytic phase. The results were
compared with those obtained in asymptomatic normolipidemic sub-
jects, patients with type IV hyperlipoproteinemia, and patients with
type II diabetes mellitus. CRF patients had reduced concentrations of
ApoA-I and ApoA-LI, normal levels of ApoB and ApoC-I, and in-
creased concentrations of ApoC-!! and, in particular, of ApoC-Ill.
There was a significant reduction in the levels of ApoE, especially in
male patients. In comparison with type IV, hyperlipoproteinemic
patients, CRF patients had lower concentrations of ApoA-I, ApoA-II,
ApoB, ApoC-I and, particularly, ApoE; there was no difference in
ApoC-Ill levels reflecting the hypertriglyceridemia common to both
disorders. Simitar but less marked differences were also found in
comparison with type II diabetics. The findings suggest that in CRF, the
accumulation of ApoC-III-enriched lipoprotein particles accompanied
by a moderate hypertriglyceridemia may be caused more probably by
an impaired catabolism than overproduction of triglyceride—rich lipo-
proteins. CRE patients with vascular disease tended to have higher
serum concentrations of triglycerides, cholesterol and ApoB and lower
ApoA-I/ApoC-IH and ApoA-I/ApoB ratios than patients without vas-
cular disease.
The recognized importance of plasma apolipoproteins for the
structural integrity and functional specificity of lipoprotein
particles has led to the concept of apolipoprotein profiling as a
new means of recognizing and classifying dyslipoproteinemic
states [I, 2]. The usefulness of apolipoprotein profiling has been
further enhanced by recent studies indicating that apolipopro-
teins may be better predictors of coronary artery disease than
lipids [3—7].
In addition to a high frequency of hypertriglyceridemia,
chronic renal failure (CRF) is associated with other risk factors
for the development of vascular disease including hypertension,
hyperuricemia and hyperparathyroidism [8—10]. It is still uncer-
tain whether the uremic patients are more prone to develop
atherosclerotic disease [11], but a more rapid progression of
already existing disease is often observed [12]. The role of the
usually moderate hypertriglyceridemia in this disease process is
difficult to assess. In nonuremic patients, triglyceride elevation
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is most frequently associated with increased levels of
triglyceride—rich, very low density lipoproteins (VLDL) which
represent a mixture of particles differing in density, size, charge
distributions and apolipoprotein composition [13—17]. In nor-
molipidemic subjects, these particles contain various combina-
tions of apolipoproteins B, C and E with the major lipoprotein
species (LP-B:C:E) characterized by the presence of all three
apolipoproteins [18, 19].
In contrast to numerous studies on the plasma lipid profile in
CRF [20—23], there are only a few reports on the direct
measurement of some apolipoproteins in uremic patients
[24—30]. We have already shown that patients with various
types of familial hypo- and hyperlipoproteinemias exhibit char-
acteristic apolipoprotein profiles that may be used either as
valuable diagnostic and monitoring tools, or as clues about the
chemical nature of accumulating lipoprotein particles as defined
by their apolipoprotein composition [1, 2, 31]. To establish
whether CRF is also characterized by a specific apolipoprotein
profile, we have determined the levels of apolipoproteins A-I,
A-lI, B, C-I, C-Il, C-Ill, and E in a well defined group of
patients with chronic renal failure before dialysis, and evaluated
their possible relation to clinical vascular disease. The apolipo-
protein profile of patients with CRF was also compared with
apolipoprotein profiles of two other types of moderate
hypertriglyceridemia, that is, type IV hyperlipoproteinemia and
type II diabetes mellitus.
Methods
Patients
Fifty—six Swedish patients with chronic renal failure were
investigated. Thirty—three male patients had a mean age of 44.8
14.6 years and twenty—three female patients had a mean age
of 51.0 11.9 years. The renal diagnosis was chronic glomer-
ulonephritis in seventeen patients, chronic interstitial nephritis
in twenty—four patients, polycystic kidney disease in twelve
patients, and other or unknown diagnosis in three patients. All
patients had advanced renal failure with mild or moderate
uremic symptoms. The patients were on an ad libitum diet and
the individual food intake was not monitored. The mean body
mass index (BMI) was 25.1 4.7 kg/m2 and the mean glomer-
ular filtration rate was 8.1 3.6 ml/min/1.73 m2 BSA.
Forty—eight patients were treated with beta blocking agents
for hypertension. Since treatment with beta blocking agents has
been reported to affect lipoprotein levels, patients on beta
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blocking treatment (N = 46) and patients without beta blocking
treatment (N 8) were separated, but no significant difference
could be found in any variable between the two groups of
patients. Patients with diabetes mellitus, thyroid disorders or
treatment with other drugs known to influence lipid metabolism
were excluded from the study. The patients were treated with
diuretics, antihypertensive drugs and sodium bicarbonate as
appropriate. No patient received steroid or immunosuppressive
treatment.
Control subjects
Two groups of control subjects were recruited among
healthy, asymptomatic men and women. One group, referred to
as "American controls," consisted of 74 white men and 82
white women with a mean age of 38.6 16.5 years. They were
classified as normolipidemics according to the recommended
criteria of the Lipid Research Clinics of the National Institutes
of Health, Bethesda, Maryland [32] and were employees of the
Oklahoma Medical Research Foundation.
The second control group, referred to as "Swedish con-
trols," consisted of nine men and eight women with a mean age
of 37.5 8.2 years. They were all employees of the Department
of Medicine, University of Goteborg, Sweden. There were no
differences in serum lipids, lipoprotein, cholesterol or apolipo-
protein values between the two control groups. Therefore the
two groups were pooled when evaluating differences with the
patient population.
Reference populations
Two American hypertriglyceridemic populations were re-
cruited for comparison with the uremic patients. One group
consisted of thirteen non-obese normotensive men aged 57.8
5.4 years with type IV hyperlipoproteinemia, but otherwise
healthy, asymptomatic and consuming a regular American diet.
Their mean serum triglyceride value of 4.1 1.6 mmol/liter was
not significantly different from that of the uremic male patients.
The second group consisted of 58 men and 107 women aged
55.3 12.7 years with type II diabetes mellitus with a mean
duration of disease of 6.8 6.8 years. The mean body mass
index (BMI) was 31.6 6.3 kg/rn2 and 61% of the patients were
hypertensive (blood pressure >140/90 mm Hg). Thirty—five
percent of the patients were treated with insulin, 43% with oral
hypoglycemic agents and 22% with diet only. The mean fasting
blood glucose was 201 70 mg/dl and the mean HbA1 value was
11.5 3.6%. Although elevated, the mean serum triglyceride
value of 2.4 mmol/liter was lower than that of the uremic
patients.
Methods
Lipid and apolipoprotein analyses
Blood samples were drawn by antecubital venipuncture after
an overnight fast of at least 12 hours. In patients and Swedish
controls, serum cholesterol was determined according to
Cramer and Isaksson [33], and serum triglyceride was estimated
by the method of Carlson [34]. HDL-cholesterol was deter-
mined in the supernate after precipitation with heparin-MnCl2
[35]. VLDL-cholesterol was assayed in the supernate after
ultracentrifugation at density 1.006 g/ml, and LDL-cholesterol
was estimated as the difference between the cholesterol content
of the infranate at density 1.006 g/ml and HDL cholesterol.
Total cholesterol, triglyceride and cholesterol contents of
VLDL, LDL and HDL of American controls were measured
according to the procedures used by the Lipid Research Clinics
Program [32]. Apolipoprotein analyses were carried out by
electroimmunoassays according to previously described proce-
dures for ApoA-I and ApoA-II [36], ApoB [37], ApoC-I [381,
ApoC-Il [38], ApoC-Ill [39] and ApoE [40]. The heparin
precipitated (HP = VLDL + LDL) and heparin non-precipita-
ted (HS = HDL) lipoproteins for measurement of ApoC-Ill-
HS/ApoC-III-HP ratio [41] were isolated by a modification [42]
of the heparin-MnCl2 method [43] in that a Mn concentration
of 0.092 M was used instead of 0.046 M as originally described.
Serum samples collected in GOteborg from patients and
Swedish controls were shipped by air freight from Goteborg to
Oklahoma City for the determination of apolipoproteins. The
analyses of apolipoproteins were carried out three to four days
after the blood collection. All serum samples contained
Thiomerosal (0.1 mg!ml) as a preservative.
Cardiovascular disease
The case records of all patients were reviewed for clinical
evidence of vascular disease within five years of sampling for
apolipoprotein determination. Clinical vascular disease was
judged to be present in cases of myocardial infarction, severe
coronary atherosclerosis (coronary angioraphy, exercise
ECG, autopsy), disabling angina pectoris, cerebral vascular
lesion (stroke or symptoms of cerebral ischemia) or peripheral
arterial insufficiency requiring surgery. Suspected vascular dis-
ease was judged to be present in cases with moderate effort
angina pectoris, cardiac arrythmias not explained by electrolyte
disturbances or drug treatment and sudden death. The distribu-
tion of main vascular complications among the patients was as
follows:
Myocardial infarction
Severe coronary atherosclerosis, without
myocardial infarction
Disabling angina pectoris
Cerebral vascular lesion
Peripheral arterial insufficiency
Moderate angina pectoris
Atrial fibrillation
Sudden death
Male Female
Nine male and six female patients had well documented
clinical vascular disease while six male and four female patients
were suspected of having vascular disease. Taken together 45%
of the male and 43% of the female patients had definite or
suspected vascular disease.
Statistical methods
Means, standard deviation and standard errors of the means
were calculated by conventional methods. Wilcoxon's two
sample tests was used for testing the significance of differences
between means, and the correlation coefficients were calculated
by Spearmans rank correlation method.
Results
Serum triglycerides and cholesterol were significantly higher
in patients than either the American or Swedish controls (Table
4
2
4
2
2
2
3
3
370 Attman et a!
Table 1. Serum cholesterol, triglycerides and cholesterol distribution in VLDL, LDL and HDL in patients with chronic renal failure and
American and Swedish control subjects (values are given as mean sD)
Serum VLDL LDL HDL
Triglyceride Cholesterol Cholesterol
Subjects mmollliter mmollliter
All patients 3.22 205"(N = 56)
6.28 140"
(N = 56)
1,38 1,43"(N 30) 3.43 1.27(N = 30) 1.14 0.34"(N = 35)
American controls 0.98 0.37
(N = 149)
4.83 0.90
(N = 149)
0.31 0.15
(N = 109)
3.19 0.80
(N 108)
1.40 0.35
(N = 116)
Swedish controls 0.93 0.28
(N 17)
5.07 0.67
(N = 17)
0.42 0.19
(N = 5)
3.20 0.69
(N = 5)
1.43 0.48(N = 13)
Male patients 3.43 2.18"(N = 33)
6.18 1,51d
(N = 33)
1.51 1.52"
(N = 21)
3.22 1.25
(N = 21)
1.19 0.36(N 23)
Male American controls 1.06 0.40
(N = 69)
4.83 0.89
(N = 69)
0.32 0.16
(N = 48)
3.31 0.88
(N = 48)
1.21 0.23(N = 49)
Female patients 2.90 I.851(N 23) 6.44 1.22"(N = 23) 1.10 1.14"(N = 9) 4.06 1,61(N = 9) 1.14 0.31e(N = 12)
Female American controls 0.93 0.35
(N = 80)
4.83 0.92
(N = 80)
0.29 0.13
(N = 61)
3.10 0.71
(N = 60)
1.55 0.36
(N = 67)
Significance of difference between patients and American controls:
a P < 0.05
b P < 0.01
P < 0.001
d < 0.0001
Table 2. Serum apolipoproteins in patients with chronic renal failure and American and Swedish controls (Values are given as mean SD)
Subjects
Serum apolipoproteins mgldl
A-I A-H B C-I C-I! C-Ill E
All patients 90.0 24.2c(N = 35)
43.3 8.7
(N = 18)
109.3 44.8 9.3 2.9 4.4 2.Oa(N 56) (N = 33) (N = 14) 18.5 6.3c(N = 55) 8.5 44b(N = 43)
American controls 136.0 27.5
(N 155)
69.0 14.1
(N = 128)
99.0 26.8 9.0 2.6 3.2 0.9
(N = 155) (N = 37) (N = 61)
8.3 2.4
(N = 156)
10.9 3.9
(N = 153)
Swedish controls
Male patients
144.5 40.1
(N = 17)
80.2 20.8c
(N = 19)
63.7 13.6
(N = 16)
44,9 7,9C
(N = 11)
97.0 20.3 8.1 2.0 3.2 0.6
(N = 16) (N = 5) (N = 10)
105.5 49.9 9.4 3.2 4.4 2.3
(N = 33) (N = 22) (N = 9)
9.1 2.7
(N = 16)
18.6 7.2c(N = 32)
11.1 2.6
(N = 16)
7.1 46b
(N = 23)
Male American controls 124.0 22.6
(N = 74)
62.6 11.5
(N = 55)
106.3 28.8 8.1 2.4 3.2 0.9
(N = 73) (N = 24) (N = 28)
8.1 2.7(N = 74)
10.2 3,3(N = 73)
Female patients 101.6 23.4(N = 16)
40.8 9,9'
(N = 7)
114.8 36,6a 9.0 2.3a 4.5 1.6
(N = 23) (N = 11) (N = 5)
18.3 5,OC(N = 23)
10.0 3.8(N = 20)
Female American controls 146.3 27.6
(N = 81)
74.0 16.3
(N = 73)
93.2 23.7 10.5 2.5 3.2 1.0
(N = 82) (N = 13) (N = 33)
8.4 2.0
(N = 82)
11.6 4.3(N = 80)
Significance of difference between patients and American controls:
a P < 0.05b < 0.001
"P < 0.0001
1). The triglyceride levels were markedly increased with 66% of
the patients having triglyceride values above 2.2 mmoltliter.
The elevated levels of triglycerides and cholesterol were re-
flected in the elevation of the VLDL cholesterol both in male
and female patients. The female patients also had an increase of
LDL and a decrease of HDL cholesterol.
Apolipoprotein A-I and A-TI were significantly lower in
patients than in either Swedish or American controls (Table 2).
Similary to control subjects, the concentration of ApoA-I in
male patients was lower than in female patients. ApoB levels
were slightly increased in female patients but not in males.
Female but not male patients also had slightly lower levels of
ApoC-I. Apolipoprotein C-Il was slightly elevated in all pa-
tients, reaching statistical significance only when compared to
all American controls. In contrast, both male and female
patients had a highly significant elevation of ApoC-tIl levels in
comparison with both control groups. A statistically significant
decrease in the concentration of ApoE in the patient population
was primarily due to a significant decrease of this apolipopro-
tein in the male patients.
The ApoA-I/ApoC-III and ApoB/ApoC-Ill ratios (Table 3)
were the most significant discriminators between the patients
and the controls for both sexes. There was also a significant
reduction of the ApoA-I/ApoB ratio in the patients.
The most striking difference between the uremic patients and
the type IV patients with a similar degree of hypertriglycer-
idemia was a pronounced decrease of ApoE levels in the uremic
population (Table 4). The uremic male patients had significantly
lower levels of ApoA-I, ApoA-II, ApoB and ApoC-Il than
patients with type IV disease. Although the mean triglyceride
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ApoA-I/
Subjects ApoB
ApoC-III-HS/ApoC-III-HP is the ratio of ApoC-Ill in heparin super-
nates (HS, heparin non-precipitable lipoproteins) and heparin precipi-
tates (HP, heparin precipitable lipoproteins). Values are given as
mean SD.
a Significance of difference between patients and American controls
P < 0.01
level was slightly lower in the uremic patients, the mean
ApoC-Ill value tended to be higher than in the type IV patients.
There was no difference in the apolipoprotein ratios between
the uremic patients and patients with type IV hyperlipopro-
teinemia.
Despite lower cholesterol values, patients with type II diabe-
tes mellitus had significantly higher concentrations of apolipo-
proteins A-I, B and E than patients with CRF (Table 5). On the
other hand, uremic patients had significantly higher levels of
ApoC-Ill relative to serum triglyceride concentrations than
diabetics.
The distribution of ApoC-Ill in HDL vs LDL and VLDL,
reflected in the apo C-III-HS/apo C-Ill-HP ratio (Table 3),
showed a marked increase of ApoC-IlI in the lower density
classes, which was more pronounced in the uremics than in
patients with type IV disease or diabetes.
The mean ApoA-I/ApoC-III and ApoB/ApoC-Ill ratios were
considerably higher in the diabetics than in patients with CRF
(16.7 vs. 6.2 and 15.1 vs. 6.5).
Correlations among variables
Triglycerides were highly significantly correlated with VLDL-
cholesterol, ApoC-Il, ApoC-Ill and ApoC-Ill in heparin—
precipitated lipoproteins, and less strongly but significantly
with ApoB, ApoC-I, ApoE and total cholesterol levels; there
was a significant negative correlation between triglycerides and
HDL-cholesterol. ApoB levels were significantly correlated
with ApoE levels. ApoA-I was significantly correlated with
ApoA-II but not with HDL-cholesterol or any other lipid or
apolipoprotein.
Vascular disease
The selection of patients depended on their availability for
the study with a special interest towards patients with
hypertriglyceridemia in renal failure. For this reason, the pres-
ent patient group cannot be used to determine the incidence of
vascular disease in a uremic population. Patients with definite
vascular disease had a higher level of serum cholesterol (7.1 vs.
5.8 mmol/liter, P < 0.05) and ApoB (138 vs. 97 nig/l00 ml, P <
0.05) and a lower ratio of (7.2 vs. 15.0, P < 0.05) ApoA-I/ApoC-
III in VLDL + LDL (heparin precipitate) in comparison with
patients without evidence of vascular disease (Table 6). The
ApoC-Ill values were not significantly higher in the vascular
disease patients (21.0 vs. 17.9, P = 0.07). There were no
significant differences in other variables between the two
groups of patients. Patients with both the ApoA-I/ApoC-III
ratio below normal —2 SD (that is, <7) and ApoB levels above
normal +2 SD (that is, 150 mg/l00 ml) were studied for presence
of vascular disease, and in this group eight out of ten patients
had definite or suspected vascular disease. Thus, patients with
elevated ApoB level and low ApoA-I/ApoC-III ratios seemed to
be prone to develop vascular disease in renal failure.
Discussion
The well established high incidence of hypertriglyceridemia
[20—24] in male and female patients with CRF has again been
demonstrated in this study. Triglyceride levels were well cor-
related with the levels of VLDL-cholesterol and, among apo-
lipoproteins, with the concentrations of ApoC-Il and ApoC-Ill.
The female patients had higher concentrations of LDL-chole-
sterol than male patients possibly due to a more efficient
conversion of their VLDL to LDL. This interpretation is also
supported by the fact that female patients had lower levels of
VLDL-cholesterol and higher values for ApoC-III-HS/ApoC-
Ill-HP ratios than male patients.
The most characteristic feature of the apolipoprotein profile
in uremic patients, in comparison with that of control subjects,
was the marked elevation of ApoC-Ill levels. Increased con-
centrations of serum-ApoC-Ill reflected an absolute and rela-
tive elevation of this apolipoprotein in heparin—precipitable
lipoproteins (VLDL + LDL). There was no comparable change
in the mean levels of apolipoproteins B, C-I, C-Il and E, the
other major apolipoproteins of heparin—precipitable lipopro-
teins. Furthermore, the male patients had normal concentra-
tions of ApoB while a slight increase was found in the female
patients. The ApoE levels were significantly lower than con-
trols in male but not in female patients. However, female
patients also tended to have lower concentrations of ApoE than
the corresponding controls. Earlier studies of apolipoproteins in
CRF have not covered the whole spectrum of apolipoproteins
and have almost exclusively been performed in patients on
hemodialysis [25—29, 44—46) which might explain some discrep-
ancies with our findings, especially with respect to ApoE levels.
ApoB has been reported to be either subnormal [27, 29] or
slightly elevated [44, 47]. The findings of Staprans, Feltz and
Zacherle [44] of a reduced ApoC-Il to ApoC-Ill ratio could not
be confirmed in our study. The significantly reduced levels of
ApoA-I and ApoA-II were well correlated in patients with CRF,
indicating a decrease in the concentration of lipoprotein parti-
cles containing both ApoA-I and ApoA-II. Similar results have
been reported by Savdie et al [46]. In other studies, levels of
ApoA-I have been found to be similar or slightly reduced
[27—29, 45, 471! in comparison to those of control subjects. The
selection of patients and control subjects maybe responsible, at
least in part, for these slightly divergent results.
Table 3. Ratios of serum apolipoproteins in patients with chronic
renal failure and American and Swedish controls
All patients 0.79 0.4a(N = 35)
American 1.46 0.5
controls (N = 154)
Swedish controls 1.45 0.6(N = 15)
Male patients 0.73 0.4a(N = 19)
Male American 1.25 0.4
controls (N = 73)
Female patients 0.86 o.3(N = 16)
Female American 1.64 0.5
controls (N = 81)
ApoA-I/
ApoC-Ill
6.15 33
(N = 35)
17.3 4.7
(N = 155)
15.8 6.2
(N = 15)5.83 34
(N = 19)
16.5 4.8
(N = 74)
6.53 3.2a
(N = 16)
18.0 4.5
(N = 81)
ApoB/
ApoC-Ill
6.46 3.0
(N = 55)
12.6 4.0
(N = 155)
11.1 2.6
(N = 16)
6.27 3.V'
(N = 32)
13.9 4.1
(N = 73)
6.73 3.la(N = 23)
11.6 3.8
(N = 82)
ApoC-Ill-
HSIApoC-
Ill-HP
0.55 0.4
(N = 19)
2.07 LI
(N = 116)
1.83 0.8
(N= II)
0.34 0.2a
(N = 10)
1.85 1.3
(N = 50)
0.78 0.4a
(N = 9)
2.23 0.8
(N = 66)
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Table 4. Serum lipids and apolipoproteins in male patients with chronic renal failure and male subjects with type IV hyperlipoproteinemia
(values are given as mean so)
Subjects
Serum lipids mmoll!itei Serum apolipoproteins mgldl
Triglyceride Cholesterol A-I A-Il B C-I! C-Ill E
Chronic renal failure
Type IV hyperlipo-
proteinemia
3.43 2.18(N = 33)
4.09 1.60(N = 12)
6.18 1.51
(N = 33)
6.03 0.94
(N 12)
80.2
(N =
116.7
(N =
20.8*
19)
22.0
12)
44.8
(N =
61.6
(N =
7,9C
II)
9.0
12)
105.5 49,9b
(N = 33)
136.8 28.0
(N = 12)
4.4 2.3(N 9)
7.0 2.0
(N = 12)
18.6 7.2
(N = 32)
17.1 4.8
(N = 12)
7.1 46d
(N = 23)
20.5 6.7(N = 12)
Significance of difference:
P < 0.05
"P < 0.01
P < 0.001
d P < 0.0001
Table 5. Serum lipids and apolipoproteins in patients with chronic renal failure and type II diabetes mellitus (values are given as mean so)
Subjects
Serum Serum apolipoproteins
Triglyceride Cholesterol A-I B C-Ill E
Chronic renal failure
Type II diabetes mellitus
3.22 :t 2.05c
(N = 56)
2.37 2.16
(N = 138)
6.28 I .40c(N = 56)
5.34 1.18(N = 138)
90.0 24.2c(N = 35)
127.4 34.1
(N 165)
109.3 448b 18.5 6.3c
(N = 18) (N = 55)
129.8 39.2 11.9 7.5(N = 165) (N =165)
8.5 44
(N = 43)
11.4 7.5
(N = 165)
Significance of difference:
aP < 0.05b < 0.001
P < 0.0001
The unique characteristics of the apolipoprotein profile of the
CRF patients are further underlined by the comparison with the
reference populations with hypertriglyceridemia as a common
denominator which, to our knowledge, has not been demon-
strated earlier. These patients also had an elevation of ApoC-Il!
as a consequence of hypertriglyceridemia, but they differed
from CRF patients by having marked elevation of ApoE and a
moderate increase of ApoB. Furthermote, despite higher HDL-
cholesterol values, the ApoA-L anti A-Il levels were even more
reduced in the uremic patients than in patients with type IV
hyperlipoproteineniia or type II diabetes.
These results show that CRF patients have a characteristic
apolipoprotein profile in comparison with both the normal sub-
jects and patients with other forms of hypertriglyceridemia.
Whereas ApoC-Ill values cannot be used as a differentiating
criterion, the apoliproteins A-I, A-I!, B and E are more suitable
than serum cholesterol or triglycerides for that purpose, These
differences also suggest that the underlying metabolic deffects in
CRF are not the same as in other forms of hypertriglyceridemia.
Although apolipoprotein profiles of patients with primary or
secondary hyperlipoproteinemias cannot be utilized as absolute
diagnostic criteria, they may offer very useful clues about the
nature of accumulating lipoprotein particles [1, 2]. In patients
with CRF, the significant correlation between ApoC-Ill and
serum triglyceride and VLDL-cholesterol and a disproportion-
ate increase in the levels of ApoC-Ill, in comparison with the
levels of ApoC-! and ApoC-Il, suggest the accumulation of
triglyceride—rich particles with ApoC-Ill as one of their major
protein constituents. A positive and highly significant correla-
tion between ApoB and ApoE levels, in the absence of any
significant changes in the absolute concentration of these two
apolipoproteins, suggests the possible presence of lipoprotein
particles characterized by ApoB and ApoE as the main com-
ponents of their protein moiety. Preliminary results of our
ongoing studies on the identification of discrete lipoprotein
particles in patients with CRF indicate the occurrence of both
types of these lipoproteins. The ApoB and ApoE containing
particles may be similar to the late pre-beta lipoproteins (LP-/3)
detected by agarose electrophoresis at high frequency in pa-
tients with CRF [48] and to the cholesterol ester—rich beta, very
low density lipoproteins (fJ-VLDL) found in patients with type
III hyperlipoproteinemia [49].
Subjects
No vascular disease
Table 6. Serum lipids and apolipoproteins in chronic renal failure patients without clinical evidence of vascular disease and in patients with
clinical evidence of vascular disease (values are given as mean SD)
Vascular disease
Triglyceride
3.06 2.24
(N = 31)
3.92 2.09
(N= 15)
Serum Serum apolipoproteins (mgldl)
A-I A-LI B C-Il C-Ill ECholesterol
5.97 1.30(N = 31)
7.06 J44*(N = 15)
Significance of difference:
a p < 0,05
90.3 23.4
(N = 19)
86.4 25.3
(N = 10)
40.8 4.6
(N= 11)
42.1 10.4
(N =5)
97.4 33.2
(N = 31)
137.9 51.0*(N = 15)
4.4 2.2
(N = 9)
4.2 2.0
(N = 4)
17.9 6.6
(N = 30)
21.0 6.2
(N 15)
8.3 4.9
(N = 26)
9.3 2.8(N = 10)
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The surprising finding of low ApoE values is not readily
explained. Blume et a! [501 have recently suggested that the
kidney might be a source for the production of apolipoprotein E
and the possibility that a reduced renal parenchyma contributes
less to the serum pool of ApoE than in normal subjects should
be further explored.
A number of studies have indicated that both an impaired
removal and an increased production of triglyceride—rich lipo-
protein particles contribute to the hypertriglyceridemia of
chronic renal failure [22, 26, 46, 51, 52]. Our earlier studies
indicate, however, that a defective removal mechanism may be
a more significant contributing factor than an increased pro-
duction of triglyceride—rich lipoproteins [22]. This view is
supported by studies demonstrating reduced plasma posthepa-
rin—lipolytic activities and a decreased triglyceride clearance in
CRF [23, 53—571. Moreover, findings such as reduced fractional
turnover rates of VLDL triglyceride [45, 51] and absolute
and/or relative increases of triglyceride in VLDL, LDL and
HDL [21, 26] the identification of ApoB-48 in VLDL, increased
levels of ApoA-IV in VLDL and LDL, and ApoC and ApoE in
LDL [26] are also suggesting an incomplete degradation and/or
uptake of triglyceride—rich lipoproteins and consequent accu-
mulation of remnant particles. Recently Gonen et al [58]have
reported that LDL from dialysis patients have abnormal com-
position and are less readily taken up and degraded by fibro-
blasts than normal LDL.
Our finding of low ApoE concentrations in CRF might
indicate the formation of triglyceride—rich lipoprotein particles
with abnormal apolipoprotein characteristics. A relative defi-
ciency of ApoE could make these remnant particles a less
attractive substrate for further degradation and, as a conse-
quence, with result in their accumulation in the plasma.
The triglyceride elevation found in familial hypertrigly-
ceridemia [58, 59] and diabetes mellitus [60, 61] has been
attributed to the overproduction of triglyceride—enriched
VLDL. These patients are not only characterized by elevated
levels of ApoC-Ill but also by increased concentrations of
ApoB and ApoE [621. Since these two latter apolipoproteins are
not elevated in most patients with CRF it is less likely that
overproduction of triglyceride—rich VLDL plays an important
role in the development of uramic dyslipoproteinemia. Further
insight may be gained by measuring the apolipoprotein distri-
bution in lipoprotein particles.
One of the main reasons for studying uremic hyperlipopro-
teinemia has been its possible relationship to and role in the
development of atherosclerosis. It was therefore of consider-
able interest to establish whether patients with CRF and clinical
evidence of atherosclerosis exhibited any particular traits in
their apolipoprotein profile. Results showed that patients with
vascular disease tend to have higher concentrations of plasma
cholesterol and ApoB and lower values for ApoA-I/ApoC-III
and ApoA-I/ApoB ratios than patients without vascular dis-
ease; patients with documented vascular disease also had
higher concentrations of serum triglyceride and ApoC-Ill, but
these increases did not reach statistical significance. In an
analysis of cardiovascular risk factors in dialysis patients, Hahn
et a! [9] observed that patients with cardiovascular disease had
higher serum triglyceride values and lower HDL-cholesterol,
but no change in serum cholesterol when compared to patients
without disease. These initial results suggest the usefulness of
lipid and apolipoprotein profiles as potential predictors for
coronary artery disease in patients with CRF, but additional
cross—sectional and prospective studies are warranted in order
to fully realize this potential.
In summary, the main characteristics of apolipoprotein pro-
file in patients with CRF are significantly decreased concentra-
tions of apolipoproteins A-I, A-lI and E and a significantly
increased concentration of ApoC-Ill. In contrast to the apolipo-
protein profile of uremic patients, patients with primary hyper-
triglyceridemia (phenotype IV) have significantly higher levels
of ApoB and ApoE, while patients with insulin independent
diabetes mellitus have significantly higher concentrations of
ApoA-I and ApoB and a lower concentration of ApoC-Ill.
These results indicate different underlying defects in these three
types of moderate hypertriglyceridemia and suggest that a
catabolic impairment leading to the accumulation of remnant
lipoprotein particles may be the main derangement of lipid
transport in CRF. A characteristic apolipoprotein profile re-
flecting the degree and extent of accumulating remnant particles
appears to be a potential predictor of coronary artery disease in
patients with CRF.
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